

Michael M. Copenhaver, PhD

Revised December 2025

Business Address

University of Connecticut
Department of Allied Health Sciences, U-2101
358 Mansfield Road
Storrs, CT 06269-2101
Michael.Copenhaver@UConn.edu

Education

- Yale University School of Medicine, New Haven, CT (2000). Post-doctoral training in clinical psychology in the Department of Psychiatry, Division of Substance Abuse.
- Yale University School of Medicine, New Haven, CT (1999). Clinical psychology internship training in the Department of Psychiatry, Division of Substance Abuse.
- Virginia Tech, Blacksburg, VA (1994-1999). Doctoral training in clinical psychology (Ph.D.) in the Department of Psychology. Dissertation title: Testing a social-cognitive model of intimate abusiveness among substance dependent males.
- Villanova University, Villanova, PA (1987-1989). Master of Science in experimental psychology (M.S.) in the Department of Psychology. Thesis title: The Effect of Spatial Contrast Sensitivity on Pseudo-isochromatic Test Performance.
- Clemson University, Clemson, SC (1983-1987). Bachelor of Art in Psychology (B.A.) in the Department of Psychology.

Professional Experience

- **Professor with tenure**, Department of Allied Health Sciences, & Licensed Clinical Psychologist in CT #002323 (2017- Present).
- **Associate Professor with tenure (2010-2016); Assistant Professor (2007-2010)**. Department of Allied Health Sciences, University of Connecticut, Storrs, CT. 75%/25% (Research/Teaching) tenure track academic appointment.
 - Course Responsibilities:
 - 2008-Present – Teach a yearly core course for the graduate program, Intervention for At-Risk Populations (GPAH 5319) – A core graduate course for the Allied Health Sciences graduate program in Health Promotion (GPAH) that fulfills a component of the certificate program in health promotion (CHES) and the licensure requirements for doctoral students in-Clinical Psychology.

- 2014-Present – Teach a yearly core course for the graduate program – Critical Issues in Health Promotion (GPAH 6324) – a core graduate course for the Allied Health Sciences in GPAH program designed to enhance graduate students’ understanding of health promotion and disease prevention in order to incorporate this knowledge into their practice of health promotion.
- 2009-2014 – Developed and taught an undergraduate writing-intensive (W) course each semester – Research Methods for the Health Professional (AHS 4241) – a core course for all Allied Health Sciences undergraduates involving a 2-hour lecture and 1 hour discussion.
- **Assistant Research Professor (2002-2007).** Department of Psychology, Center for Health, Intervention, & Prevention (CHIP), University of Connecticut, Storrs, CT
 - PI Responsibilities:
 - Responsible for designing and conducting federally funded behavioral HIV prevention research. Developed and taught a graduate course in clinical psychology, Integrative Treatment with Special Populations (PSYCH 317), which is an intensive clinical course on assessment and treatment with challenging cases including substance abuse, domestic violence, child maltreatment, and sexual dysfunctions.
- **Associate Research Scientist (Licensed Clinical Psychologist) (1999-2002).** Department of Psychiatry, Yale University School of Medicine, New Haven, CT. Clinical Psychology Fellow
- **Graduate Instructor (1998-1999).** Department of Psychiatry, Yale University School of Medicine, New Haven, CT. Department of Psychology, Virginia Tech, Blacksburg, VA.
 - Instructor Responsibilities:
 - Taught Research Methods, Psychology Research Methods, Social Psychology, Personality Assessment, Cognitive Psychology Labs, and Introductory Psychology Labs.
- **Research Associate (1989-1994).** CAE Link Corporation, Fairfax, VA
 - RA Responsibilities:
 - Conducted human factors research/grant writing for government contractor.

License and Memberships

- Licensed Clinical Psychologist in CT (#002323; since 1999); Health Psychology and Addiction focus
- American Psychological Association – Member (since 1994)
- Institute for Collaboration on Health, Intervention, and Policy (InCHIP) – Member (since 2002)
- College on Problems of Drug Dependence – Regular Member (since 2003)
- American Public Health Association – Member (since 2013)
- Society of Behavioral Medicine (2016-present)

Committees

- 2019-present, Interdisciplinary Opioid Research Group - InCHIP
- 2018-present, Member, Advisory Committee to the CAHNR Dean on PTR
- 2018-2019, Search Committee Member – Assistant Professor - Health Disparities focus
- 2017, Interim Co-Director, Graduate Programs in Health Promotion Sciences
- 2016-present, Co-Director, Grant Proposal Incubator (InCHIP)
- 2009-present, Editorial Board member, AIDS & Behavior
- 2013-2016, Chair, Health Promotion Sciences - PhD Program Development Committee
- 2015-2016, University Task Force Committee - New School of Public Health/Health Sciences
- 2013-2015, Chair – Dept of AHS Promotion, Tenure, & Reappointment Committee
- 2013-2015, Chair, Dept of AHS, Development of PhD in Health Promotion Sciences
- 2013-2014, Search Committee Member, Dept of AHS, Assistant Professor Position (Obesity)
- 2013, Search Committee Member, CAHNR, Dept Head in AHS
- 2012–2017, Human Research Committee (invited standing committee member for College on Problems of Drug Dependence)
- 2010–2012, Chairperson, CAHNR Excellence Committee, University of Connecticut
- 2003-present, NIH and CDC Ad Hoc Grant Review Committee Member and Acting Chair

~60 NIH review panels (some of which are listed below)

- 2016, NIH Study Section member, Behavioral and Social Science Approaches to Preventing HIV/AIDS (BSPH)
- 2016 National Science Foundation (NSF) Review Committee Member.
- 2015 National Science Foundation (NSF) Review Committee Member.
- National Institutes of Health, Center for Scientific Review, Review Panel Member, RFA-DA-11-001 (2/11)
- National Institutes of Health, Center for Scientific Review, Review Panel Member, ZDA1 LXF-L-01 (3/11)
- 2013 National Science Foundation (NSF) Review Committee Member.

- National Institutes of Health, Center for Scientific Review, SBIR Phase I & II Review Panel Member (2/10; 3/10; 5/10)
- National Institutes of Health, Center for Scientific Review; Review Panel Member, ARRA RC4 Sustainable Community-linked Infrastructure (2/10)
- National Institutes of Health, Center for Scientific Review, ZRG1 AARR-F(52) Review Panel member (12/09)
- Chairperson, Centers for Disease Control and Prevention Special Emphasis Panel (CD09-001 Panel F; 2009)
- Research Scientist Appointment Committee member (2009-present), Center for Health, Intervention, & Prevention (CHIP), University of Connecticut.
- National Institutes of Health, Center for Scientific Review, ZDA1 LXF-L (SEP) Review Panel member (03/09)
- Centers for Disease Control and Prevention PS09-002 (SEP) Review Panel member (03/09)
- Chairperson, Internal Grant Review Committee (2008-2012), Center for Health, Intervention, & Prevention (CHIP), University of Connecticut.
- Centers for Disease Control and Prevention, Peer Review Meeting for PAR07-231 (7/08)
- National Institutes of Health, Center for Scientific Review, ZDA1 MXS-M (CJDATS2) Review Panel member (11/08)
- Research Scientist Appointment Committee member (2009-present), Center for Health, Intervention, & Prevention (CHIP), University of Connecticut.
- Executive Committee member (2007-2010), Center for Health, Intervention, & Prevention (CHIP), University of Connecticut.
- Centers for Disease Control and Prevention, Peer Review Meeting for RFA PS07-003 SEP (5/07).
- Centers for Disease Control and Prevention, Peer Review Meeting for RFA PS07-004 SEP (5/07)
- National Institutes of Health, Center for Scientific Review, ZRG1 AARR-F (02) SEP Review Group Member (11/05)
- Graduate Student Grant Review Panel member (2003- present), Center for Health, Intervention, & Prevention (CHIP), University of Connecticut.
- National Institutes of Health, Center for Scientific Review, ZRG1 AARR-F (01) SEP Review
- Group Member (12/04)

Ad Hoc Review Committee member for:

- *Journal of AIDS*
- *Journal of Consulting and Clinical Psychology*
- *Drug and Alcohol Dependence*
- *Journal of Substance Abuse Treatment*
- *Addiction*
- *AIDS care*
- *Journal of Urban Health*

- *AIDS & Behavior*
- *Psychological Assessment*
- *Health Psychology*
- *AIDS Patient Care & STDs*

Research Grants

Ongoing federally-funded Research:

2K24DA051344-06 (renewal) Copenhaver (PI) 8/15/2025- 6/30/2030

National Institutes of Health, National Institute on Drug Abuse

Title: Optimizing HIV Prevention among opioid-dependent persons

Funds Requested: \$1,018,949

R01DA055534-02W1 Copenhaver (PI) 7/01/2023 - 6/30/2027

National Institutes of Health, National Institute on Drug Abuse

Using fMRI to specify brain-based mechanisms of cognitive dysfunction (Administrative Supplement to the R01 listed below).

Funds Awarded: \$1,462,149

R01DA055534 Copenhaver (PI) 9/01/2022- 8/31/2027

National Institutes of Health, National Institute on Drug Abuse

Optimizing evidence-based HIV prevention targeting people who inject drugs on PrEP

Funds Awarded: \$3,204,444

K24DA051344 (original award) Copenhaver (PI) 7/01/2020- 6/30/2025

National Institutes of Health, National Institute on Drug Abuse

Title: Optimizing HIV Prevention among opioid-dependent persons

Funds Awarded: \$1,006,964

Completed grant-funded Research:

R01DA044867 Copenhaver (PI) 9/01/2017 - 6/30/2024 (NCE)

National Institutes of Health, National Institute on Drug Abuse

Title: Testing an integrated bio-behavioral primary HIV prevention intervention among high-risk opioid-dependent persons.

Funds Awarded: \$3,772,606

K02DA033139 Copenhaver (PI) 4/01/2013 - 3/31/2019 (NCE)

National Institutes of Health, National Institute on Drug Abuse

Title: HIV Prevention and adherence among priority drug using populations

Funds Awarded: \$697,150

R01DA032290 Copenhaver (PI) 4/1/2012 – 3/31/2018 (NCE)

National Institutes of Health, National Institute on Drug Abuse

Title: Secondary HIV prevention and adherence among HIV-infected drug users

Role: PI

Funds Awarded: \$3,614,012

R01DA025943 Copenhagen (Co-I) 9/30/2008 – 06/30/2015
National Institutes of Health, National Institute on Drug Abuse
Title: Intervention of HIV, Drug Use and the Criminal Justice System in Malaysia
Role: Co-I (Altice PI)
Funds Awarded: \$125,736 (includes only my salary support)

U01 DA025282 Copenhagen (Co-I) 9/1/2008 – 6/31/2014
National Institutes of Health, National Institute on Drug Abuse
Title: Criminal Justice Drug Abuse Treatment Studies 2 (CJ-DATS 2)
Role: Co-I
Funds Awarded: \$138,000 (includes only my salary support)

2008-R-26-CDC Copenhagen (Co-I) 9/1/2008 – 8/31/2010
Centers for Disease Control and Prevention
Title: Incentivized Worksite Weight Loss Program in the Nursing Home Sector
Role: Co-I
Funds Awarded: In kind support

R21 DA021093 Copenhagen (PI) 9/30/2006 – 6/30/2009
National Institutes of Health, National Institute on Drug Abuse
Title: A Healthy Transition for Newly Released HIV-infected Prisoners
Role: PI
Funds Awarded: \$275,000

K23 DA17015 Copenhagen (PI) 9/30/03 - 7/1/08
National Institutes of Health, National Institute on Drug Abuse
Title: Optimizing HIV prevention for HIV-positive Injection Drug Users
Role: PI
Funds Awarded: \$555,304

R01 DA022122 Copenhagen (PI) 9/30/2006 – 7/1/2012
National Institutes of Health, National Institute on Drug Abuse
Title: Testing a Community-Friendly Risk Reduction Intervention for Drug Users
Role: PI
Funds Awarded: \$2,400,137

DPH/CDC #H02-436 Copenhagen (PI) 7/1/02 – 6/30/05
Department of Public Health, AIDS Division, State of Connecticut & Centers for Disease Control
Title: Harm Reduction Group Level HIV Prevention Intervention for Injection Drug Users.
Role: PI

Publications

Papers in press, published, or under review (as noted):

1. Zelenev, A., Izadidehkordi, S., & Copenhaver, M. (2025, under review). Evaluating the Cost-Effectiveness of a Bio-behavioral Community-friendly Health Recovery Program (CHRP-BB) Targeting Population Under Opioid Replacement Therapy with Elevated HIV Risk.
2. Huedo-Medina, T., Zelenev, A., Shrestha, R., Mistler, C.B., Altice, F.L., & Copenhaver, M.M. (2025). Comparing the Brief Holistic Health for HIV (3H+) to the Holistic Health Recovery Program (HHRP+) among People with HIV and Opioid Use Disorder: Results from a Randomized, Controlled Non-Inferiority Trial. PLOS ONE. PMID: PMC11542883
3. Khati, A.***, Wickersham, J., Copenhaver, M.M., Xu, R., Gautam, K., Paudel, K., & Shrestha, R. 2024. (2025). Uptake and persistence of oral pre-exposure prophylaxis (PrEP) among opioid-dependent people who inject drugs initiating PrEP for HIV prevention. Journal of Substance Use and Addiction Treatment. (In Press). doi: 10.1016/j.josat.2025.209693
4. Mistler, C., Shrestha, R., & Copenhaver, M. (2025). Implementing a biobehavioral HIV prevention intervention for people who inject drugs: a randomized controlled feasibility trial. Journal of Substance Use & Addiction Treatment.
5. Adler, T., Mistler, C., Copenhaver, M. (revised/resubmitted, 2025) The Intersectionality of Overdose, Intimate Partner Violence, and COVID-19 Among Adults Enrolled in Drug Treatment. Annals of Medicine.
6. Sujan, S.**, Khati, A.**, Paudel, K.*, Gautam, K.**, Liautaud, D.*, Crim, H.*, Wickersham, J., Copenhaver, M.M., & Shrestha, R. (2025). Non-fatal overdose and associated factors among people who use drugs: Findings from a cross-sectional study. Journal of Community Health. (2025, In Press).
7. Machavariani, E., Altice, F.L., Shrestha, R., Truebig, J., Carroll, C., Nichols, L., Ahmad, B., Copenhaver, M., & Villanueva, D. (2025). Disease Intervention Specialist Field Experience in Re-engaging Out-of-care People with HIV in Project CoRECT: A Mixed Methods Study. AIDS and Behavior. (In press). doi: 10.1007/s10461-025-04707-w
8. Mistler, C., Shrestha, R., & Copenhaver, M. (2024). Testing the Feasibility, Acceptability, and Preliminary Efficacy of Integrating Accommodation Strategies Into an HIV Prevention Intervention for People Who Inject Drugs with Cognitive Dysfunction. Journal of Substance Use and Addiction Treatment. PMID: PMC11769740.
9. Mistler, C., Huedo-Medina, T., Gunstad, J., Shrestha, R., & Copenhaver, M. (2025, revise/resubmit - under review). Testing a PrEP-focused HIV Prevention Intervention Tailored for Individuals with Opioid Use Disorder and Cognitive Dysfunction. Neuropsychiatric Disease and Treatment.
10. Ssenyonjo, J., Li, X., Shrestha, R., Leahey, T., & Copenhaver, M. (2024). Examining the validity of a self-reported ART adherence using a visual analog scale (VAS) among HIV-infected opioid-dependent individuals. AIDS & Behavior.
11. Zelenev, A., Huedo-Medina, T., Shrestha, R., Mistler, C., Altice, F., Sibilio, B., & Copenhaver, M. (2024). Comparing the brief Holistic Health for HIV (3H+) to the Holistic Health Recovery Program (HHRP+) among people with HIV and OUD: Results from a randomized, controlled non-inferiority trial. PLoS ONE. PMID: PMC11542883

12. Ssenyonjo, J., Mistler, C., Adler, T., Shrestha, R., Kyambadde, P., & Copenhaver, M. (2024, Under Review). Examining HIV Knowledge and Sexual Risky Behaviors 2 Among Female Sex Workers in Kampala, Uganda. *International Journal of Environmental Research and Public Health*.
13. Lloyd Sieger, M., Nichols*, C., Chasnoff, I. J., Putnam-Hornstein, E., Patrick, S W. & Copenhaver, M. (2023). Family Care Plans for Infants with Prenatal Substance Exposure. *Child Welfare Journal, Special Issue: Opportunities for Child Welfare to Respond to Prenatal Alcohol and Other Substance Exposures*, 101(2), 169-182.
14. Mistler, C., Shrestha, R., Gunstad, J., Collins, L., Madden, L., Huedo-Medina, T., Copenhaver, N., & Copenhaver, M. (2023). Application of the multiphase optimization strategy (MOST) to optimize HIV prevention targeting people on medication for opioid use disorder (MOUD) who have cognitive dysfunction: protocol for a MOST study. *BMJ Open*. 13(6):e071688. doi: 10.1136/bmjopen-2023-071688
15. Ssenyonjo, J., Xiaomeng, L., Shrestha, R., & Copenhaver, M. (2023, Under Review). Examining the validity of self-reported ART adherence using a visual analog scale (VAS) among HIV-infected opioid-dependent individuals. *AIDS and Behavior*.
16. Mistler, C. & Copenhaver, M. (2022). Integrating Cognitive Dysfunction Accommodation Strategies into an HIV Prevention Session: A 2-Arm Pilot Feasibility Study. *International Journal of Environmental Research and Public Health*. doi: 10.3390/ijerph19159430.
17. Mistler, C., Rosen, A., Eger, W., Copenhaver, M., Shrestha, R. (2022). Fentanyl Test Strip Use and Overdose History among Individuals with Opioid Dependence. *Austin Journal of Public Health and Epidemiology*. ISSN: 2381-9014.
18. Gunstad, J., Sanborn, V., Shrestha, R., Mistler, C., & Copenhaver, M. (2022). Latent Profile Analysis of Data from the Brief Inventory of Neurocognitive Impairment (BINI) to Develop Neuro-Cognitive Profiles Among Opioid-Dependent Patients in Drug Treatment. *Journal of Addictive Diseases*. doi: 10.1080/10550887.2022.2080626.
19. Sanborn, V., Gunstad, J., Shrestha, R., Mistler, C., & Copenhaver, M. (2022). Cognitive profiles in persons with opioid use disorder enrolled in methadone treatment. *Applied Neuropsychology: Adult*, 29, 462-468.
20. Mistler, C., Idiong, C., & Copenhaver, M. (2022). Integrating cognitive dysfunction accommodation strategies into behavioral interventions for persons on medication for opioid use disorder. *Frontiers in Public Health*.
21. Copenhaver, M., Sanborn, V., Shrestha, R., Mistler, C., Sullivan, M., & Gunstad, J. (2021). Developing a cognitive dysfunction risk score for use with opioid-dependent persons in drug treatment. *Drug and Alcohol Dependence*.
22. Copenhaver, M., Sanborn, V., Shrestha, R., Mister, C., & Gunstad, J. (2021). Association between the Brief Inventory of Neurocognitive Impairment (BINI) and objective cognitive testing among opioid-dependent persons in drug treatment. *Journal of Addictive Diseases*, 39(2):166-174. doi: 10.1080/10550887.2020.1831129.
23. Mistler, C., Shrestha, R., Gunstad, J., *Sanborn, V., & Copenhaver, M. (2021). Adapting intervention approaches for patients with opioid use disorder to accommodate their cognitive dysfunction. *General Psychiatry*, 34, e100412.
24. Mistler, C., Sullivan, M., Copenhaver, M., Meyer, J., Roth, A., Shenoj, S., Edelman, J., Wickersham, J., & Shrestha, R. (2021). Differential impacts of COVID-19 among racial-ethnic minorities with opioid use disorder. *Journal of Substance Abuse Treatment*.

25. Sullivan, M.C., Mistler, C., Copenhaver, M.M., Wickersham, J.A., Ni, Z., Kim, R.S., & Shrestha R. (2021). Race, trust, and COVID-19 vaccine hesitancy in people with opioid use disorder. *Health Psychology*.
26. Shrestha, R., DiDomizio, E. E., Kim, R. S., Altice, F. L., Wickersham, J. A., & Copenhaver, M. (2020). Awareness about and willingness to use long-acting injectable pre-exposure prophylaxis (LAI-PrEP) among people who use drugs. *Journal of Substance Abuse Treatment*, (vol. 117, pp. 108058). 10.1016/j.jsat.2020.108058.
27. Chandra, D., Altice, F., Copenhaver, M., DiDomizio, L., & Shrestha, R. (2021). Purposeful Fentanyl Use and Associated Factors among Opioid-Dependent People who Inject Drugs. *Substance Use and Misuse*. (In press).
28. Mistler, C., Curley, C., Rosen, A., El-Krabb, R., Wickersham, J., Copenhaver, M., Khatia, A., & Shrestha, R. (2021). The Impact of COVID-19 on Access to HIV Prevention Services among Opioid-Dependent Individuals. *Journal of Community Health*. doi:10.1007/s10900-021-00979-0
29. Zhou, X., Altice, F. L., Chandra, D., Didomizio, E., Copenhaver, M., & Shrestha, R. (2021). Use of Pre-exposure Prophylaxis Among People Who Inject Drugs: Exploratory Findings of the Interaction Between Race, Homelessness, and Trust. *AIDS and behavior*. 10.1007/s10461-021-03227-7.
30. Mistler, C., Sullivan, M., Wickersham, J., Copenhaver, M., & Shrestha, R. (2021). Clinical and demographic correlates of willingness to use at-home testing measures for COVID-19 among opioid-dependent individuals. *Substance Abuse*.
31. Shrestha, R., Alias, H., Wong, L. P., Altice, F., & Lim, H. (2020). Using individual stated-preferences to optimize HIV self-testing service delivery among men who have sex with men (MSM) in Malaysia: Results from a conjoint-based analysis. *BMC Public Health*, 20 (1777). doi: 10.1186/s12889-020-09832-w
32. Ni, Z., Altice, F., Copenhaver, M., DiDomizio, L., Wickersham, J., & Shrestha, R. (2020). Willingness to initiate pre-exposure prophylaxis (PrEP) and its use among opioid-dependent individuals in drug treatment. *Drug and Alcohol Dependence*. (In press).
33. Shrestha, R., Galka, J.M., Azwa, I., Lim, H., Guadamuz, T. E., Altice, F., & Wickersham, J. (2020). Willingness to Use HIV Self-Testing and Associated Factors among Transgender Women in Malaysia. *Transgender Health* (In press). doi: 10.1089/trgh.2019.0085
34. Mistler, C. B., Copenhaver, M. M., & Shrestha, R. (2020). The Pre-exposure Prophylaxis (PrEP) care cascade in people who inject drugs: A systematic review. *AIDS Behav*. doi:10.1007/s10461-020-02988-x.
35. Shrestha, R., DiDomizio, L., Kim, R., Altice, F., Wickersham, J., & Copenhaver, M. (2020). Awareness about and interest in long-acting injectable pre-exposure prophylaxis (LAIP) use in people who use drugs. *Journal of Substance Use Treatment*. (In press). doi: 10.1016/j.jsat.2020.108058
36. Sanborn, V., Gunstad, J., Shrestha, R., Mistler, C. B., & Copenhaver, M. M. (2020). Cognitive profiles in persons with opioid use disorder enrolled in methadone treatment. *Applied Neuropsychology: Adult*, 1-7. doi:10.1080/23279095.2020.1769099
37. Copenhaver, M., Sanborn, V., Shrestha, R., Mistler, C., & Gunstad, J. (2020). Validation of the Brief Inventory of Neurocognitive Impairment (BINI) among opioid-

dependent persons in drug treatment: Efficient screening that can drive tailored treatment. *Journal of Psychoactive Diseases*. doi: 10.1080/10550887.2020.1831129.

38. Mistler , C. B., Chandra, D. K., Copenhaver, M. M., Wickersham, J. A., & Shrestha, R. (2020). Engagement in Harm Reduction Strategies After Suspected Fentanyl Contamination Among Opioid-Dependent Individuals. *Journal of Community Health*. doi:10.1007/s10900-020-00928-3.

39. Mistler , C. B., Copenhaver, M. M., & Shrestha, R. (2020). The Pre-exposure Prophylaxis (PrEP) Care Cascade in People Who Inject Drugs: A Systematic Review. *AIDS Behav*. doi:10.1007/s10461-020-02988-x.

40. Sanborn, V., Gunstad, J., Shrestha, R., Mistler , C. B., & Copenhaver, M. M. (2020). Cognitive profiles in persons with opioid use disorder enrolled in methadone treatment. *Applied Neuropsychology: Adult*, 1-7. doi:10.1080/23279095.2020.1769099

41. Smith LR, Mittal ML, Wagner K, Copenhaver MM, Cunningham CO, Earnshaw VA (2020). Factor structure, internal reliability and construct validity of the Methadone Maintenance Treatment Stigma Mechanisms Scale (MMT-SMS). *Addiction*, 115(2):354-367. PMID: 31478272.

42. Shrestha, R., Altice, F., DiDomizio, L., Sibilio, B., Ranjit, Y., & Copenhaver, M. (2020). Feasibility and Acceptability of an mHealth-Based Approach as an HIV Prevention Strategy Among People Who Use Drugs on Pre-Exposure Prophylaxis. *Patient Preference and Adherence*, 14: 107-118. doi: 10.2147/PPA.S236794

43. Ranjit, Y.S., Shrestha, R., Copenhaver, M., Altice, F.L. (2020). Online HIV Information Seeking and Pre-Exposure Prophylaxis Awareness among People Who Use Drugs. *Journal of Substance Abuse Treatment*, 111: 16-22. doi: 10.1016/j.jsat.2019.12.010.

44. Ssenyonjo, J., Shrestha, R., & Copenhaver, M. (2019). Influence of stigma on prep care continuum among men who have sex with men (MSM) and transgender women in the United States. *Annals of Behavioral Medicine* 53, S320-S320

45. Shrestha, R., Altice, F., & Copenhaver, M. (2019). HIV-Related Stigma, Motivation for Medication Adherence, Viral Suppression, and Adherence to Antiretroviral Therapy (ART) among HIV-Positive Drug Users. *JAIDS Journal of Acquired Immune Deficiency Syndromes*, 80(2):166-173. doi: 10.1097/QAI.0000000000001891

46. Ssenyonjo, J., Shrestha, R. & Copenhaver, M. (2019). Influence of Stigma on Pre-Exposure Prophylaxis (PrEP) Care Continuum Among Men and Transwomen Who Have Sex with Men (MTWSM) in the United States. *International Journal of HIV/AIDS Prevention, Education and Behavioural Science.*, 5, No. 2, 134-140. doi:10.11648/j.ijhpebs.20190502.18

47. Shrestha, R., Lim, H.S., Altice, F. L., Copenhaver, M.M., Wickersham, J., Saifi, R., Halim, M.A., Naning, H., & Kamarulzaman, A. (2019). Use of Smartphone to Seek Sexual Health Information Online Among Malaysian Men Who Have Sex with Men (MSM): Implications for mHealth Intervention to increase HIV testing and reduce HIV risks. *Journal of Community Health*. doi: 10.1007/s10900-019-00713-x

48. Shrestha, R., Altice, F., Sibilio, B., Ssenyonjo, J., & Copenhaver, M. (2019). Rationale and design of an integrated bio-behavioral approach to improve adherence to pre-exposure prophylaxis and HIV risk reduction among opioid-dependent people who use drugs: The CHRP-BB study. *Contemporary Clinical Trials*, 82: 77-84. doi: 10.1016/j.cct.2019.06.012.

49. Shrestha, R., Ssenyonjo, J., Altice, F., & Copenhaver, M. (2019). An Integrated Bio-behavioral Approach to Improve Adherence to Pre-exposure Prophylaxis and Reduce HIV Risk in People Who Use Drugs: Rationale and Intervention Description. *Contemporary Clinical Trials*, 82: 77-84. doi:10.1016/j.cct.2019.06.012.
50. Shrestha, R. & Copenhaver, M. (2018). Viral Suppression among HIV-Infected Methadone-Maintained Patients: The Role of Ongoing Injection Drug Use and Adherence to Antiretroviral Therapy (ART). *Addictive Behaviors*, 85:88-93. doi:10.1016/j.addbeh.2018.05.031
51. Shrestha, R., Altice, F., Karki, P., & Copenhaver, M. M. (2018). Integrated bio-behavioral approach to improve adherence to pre-exposure prophylaxis and reduce HIV risk in people who use drugs: A pilot feasibility study. *AIDS & Behavior*, 22(8):2640-2649. doi: 10.1007/s10461-018-2099-0
52. Shrestha, R., Altice, F., Sibilio, B., & Copenhaver, M. (2018). HIV Sero-Status Non-Disclosure among High-Risk Drug Users Living with HIV: The Roles of HIV-Related Stigma, Risk Behavior, and Social Support. *Journal of Community Health*, 44(1):112-120. doi: 10.1007/s10900-018-0560-7
53. Shrestha, R., & Copenhaver, M. (2018). Exploring the Use of Pre-Exposure Prophylaxis (PrEP) for HIV Prevention among High Risk Drug Users. *Frontiers in Public Health*, 6:195 doi: 10.3389/fpubh.2018.00195
54. Shrestha, R., Karki, P., Altice, F., Dubov, O., Fraenkel, L., Huedo-Medina, T., & Copenhaver, M. M. (2017). Measuring acceptability and preferences for implementation of pre-exposure prophylaxis (PrEP) using conjoint analysis: An application to primary HIV prevention among high risk drug users. *AIDS & Behavior*, 22(4):1228-1238. doi: 10.1007/s10461-017-1851-1.
55. Shrestha, R., Altice, F., Karki, P., & Copenhaver, M. (2017). Developing a Bio-Behavioral HIV Prevention Intervention for High Risk Drug Users in Treatment: Taking into Account the Impact of Neurocognitive Impairment. *Frontiers in Immunology*, 8:561. doi: 10.3389/fimmu.2017.00561.
56. Shrestha, R., Karki, P., Huedo-Medina, T., Altice, F., Meyer, J., Madden, L., & Copenhaver, M. (2017). Correlates of willingness to use Pre-Exposure Prophylaxis and the likelihood of practicing safer drug- and sex-related risk behaviors among high-risk drug users in treatment. *Drug and Alcohol Dependence*, 173: 107-116. doi: 10.1016/j.drugalcdep.2016. 12.023
57. Bazazi, A.R., Wickersham, J., Wegman, M, Pillai, V., Culbert, G., Shrestha, R., Al-Darraj, H., Copenhaver, M., Kamarulzaman, A., & Altice, F.L. (2017). Design and implementation of a factorial randomized controlled trial of methadone maintenance therapy and an evidence-based behavioral intervention for incarcerated people living with HIV and opioid dependence in Malaysia. *Contemporary Clinical Trials*, 8:561. doi: 10.1016/j.cct.2017.05.006
58. Shrestha, R., Karki, P., & Copenhaver, M. M. (2017). Interest in Use of mHealth Technology in HIV Prevention and Associated Factors among High Risk Drug Users in Treatment. *AIDS Care*, 29(9):1144-1148. doi: 10.1080/09540121.2017.1325439
59. Shrestha, R., Weikum, D., Copenhaver, M., & Altice, F. (2017). A Self-report Measure to Detect Neurocognitive Impairment Among Incarcerated People Living with HIV in Malaysian Context: an Exploratory Factor Analysis. *International Journal of Mental Health and Addiction*, 15(4):812-825. doi: 10.1007/s11469-017-9752-0

60. Shrestha, R., Karki, P., Altice, F., & Copenhaver, M. M. (2017). Intent to use pre-exposure prophylaxis (PrEP), HIV risk behaviors, and self-report neurocognitive symptoms among high risk drug users: A mediation analysis. *Journal of the Association of Nurses in AIDS Care*, 28(4):612-621. doi: 10.1016/j.jana.2017.04.005
61. Weikum, D., Shrestha, R., Ferro, E.G., Vagenas, P., Copenhaver, M., Spudich, S., Alpert, M.D., Cabello, R., Lama, J.R., Sanchez, J., & Altice, F. (2017). An Explanatory Factor Analysis of a Brief Self-Report Scale to Detect Neurocognitive Impairment Among HIV-infected Men Who Have Sex with Men and Transgender Women in Peru. *AIDS Care*, 29(10):1297-1301. doi: 10.1080/09540121.2017.1322681
62. Shrestha, R., Copenhaver, M., Krishnan, A., Bazazi, A., & Altice, F. (2016). A Moderated Mediation Model of HIV-Related Stigma, Depression, and Social Support on Quality of Life among Incarcerated HIV-Positive Malaysian Men with Opioid Dependence. *AIDS and Behavior*, 21(4): 1059-1069. doi: 10.1007/s10461-017-1693-x
63. Shrestha, R., Copenhaver, M., Krishnan, A., Bazazi, A., & Altice, F. (2017). A Moderated Mediation Model of HIV-Related Stigma, Depression, and Social Support on Quality of Life among Incarcerated HIV-Positive Malaysian Men with Opioid Dependence. *AIDS and Behavior*. 21(4): 1059-1069. doi: 10.1007/s10461-017-1693-x.
64. Shrestha, R., Huedo-Medina, T. B., Altice, F., Karki, P., & Copenhaver, M. M. (2016). Willingness to Use Pre-Exposure Prophylaxis (PrEP): An Empirical Test of the Information-Motivation-Behavioral Skills (IMB) Model among High-Risk Drug Users in Treatment. *AIDS and Behavior*, 21(5):1299-1308. doi: 10.1007/s10461-016-1650-0
65. Shrestha, R., Weikum, D., Copenhaver, M., & Altice, F. (2017). The Influence of Neurocognitive Impairment, Depression, and Alcohol Use Disorders on Quality of Life among Incarcerated, HIV-Positive Opioid Dependent Malaysian Men: A Moderated Mediation Analysis. *AIDS & Behavior*. 21(4): 1070-1081. doi: 10.1007/s10461-016-1526-3.
66. Shrestha, R., Karki, P., Huedo-Medina, T., & Copenhaver, M. (2017). Treatment engagement moderates the effect of neurocognitive impairment on antiretroviral therapy adherence among HIV-infected drug users in treatment. *Journal of the Association of Nurses in AIDS Care*, 28(1): 85-94. doi: dx.doi.org/10.1016/j.jana.2016.09.007
67. Huedo-Medina, T. B., Shrestha, R., & Copenhaver, M. M. (2016). Modeling a Theory-Based Approach to Examine the Influence of Neurocognitive Impairment on HIV Risk Reduction Behaviors among Drug Users in Treatment. *AIDS & Behavior*, 20(8): 1646-57. doi: 10.1007/s10461-016-1394-x
68. Copenhaver, M., Shrestha, R., Wickersham, J. A., Weikum, D., & Altice, F. L. (2016). An Exploratory Factor Analysis of a Brief Self-Report Scale to Detect Neurocognitive Impairment Among Participants Enrolled in Methadone Maintenance Therapy. *Journal of Substance Abuse Treatment*, 63, 61-65. doi: 10.1016/j.jsat.2016.01.002
69. Shrestha, R., & Copenhaver, M. (2016). The Influence of Neurocognitive Impairment on HIV Risk Behaviors among High-Risk Drug Users: A Systematic Review. *Frontiers in Public Health*, 4:16. doi: 10.3389/fpubh.2016.00016
70. Karki, P., Shrestha, R., Huedo-Medina, T., & Copenhaver, M. (2016). The impact of methadone maintenance treatment on HIV risk behaviors among high-risk injection drug users: A systematic review. *Evidence-based Medicine and Public Health*, 2(e1229): 1-6. doi: 10.14800/emph.1229

71. Shrestha, R., Karki, P., & Copenhaver, M. (2016). Use of Commercial Sex Workers among Men in Nepal: Prevalence, STIs/HIV-related Risk Behaviors, and Gender Ideology. *Primary Prevention Insights*. 2016:6, 11-17. doi: <http://dx.doi.org/10.4137/PPRI.S39664>
72. Shrestha, R., & Copenhaver, M. (2016). Association between Intimate Partner Violence against Women and HIV Risk Behaviors: Findings from the Nepal Demographic Health Survey. *Violence Against Women*. 22(13): 1621-1641. doi: 10.1177/1077801216628690
73. Belenko, S., Dembo, R., Hiller, M., Copenhaver, M., O'Connell, D., Pankow, J., Albizu, Garcia, C., Oser, C., Swan, H., & Pearson, F. (2016)). HIV Stigma in Prisons and Jails: Results from a Staff Survey. *AIDS & Behavior*, 20:71–84. doi 10.1007/s10461-015-1098-7.
74. Shrestha, R., Karki, P., Pandey, S., & Copenhaver, M. (2016). Adapting an Evidence-Based HIV Prevention Intervention Targeting High-Risk Migrant Workers: The Process and Outcome of Formative Research. *Frontiers in Public Health*, 4:61. doi: 10.3389/fpubh.2016.00061
75. Smith, L. R., Earnshaw, V. A., Copenhaver, M. M., & Cunningham, C.O. (in press, 2016). Substance Use Stigma: Reliability and validity of a theory-based scale for substance-using populations. *Drug and Alcohol Dependence*.
76. Shrestha, R., Huedo-Medina, T. B., & Copenhaver, M. (2015). Sex-Related Differences in Self-Reported Neurocognitive Impairment among High-Risk Cocaine Users in Methadone Maintenance Treatment Program. *Substance Abuse: Research and Treatment*, 9:17-24.
77. Shrestha, R., Krishnan, A., Altice, F., & Copenhaver, M. (2015). A Non-Inferiority Trial of an Evidence-Based Secondary HIV Prevention Behavioral Intervention Compared to an Adapted, Abbreviated Version: Rationale and Intervention Description. *Contemporary Clinical Trials*. 44: 995-102.
78. Shrestha, R., Karki, P., & Copenhaver, M. (2015). Early sexual debut: A Risk Factor for STIs/HIV Acquisition among a Nationally Representative Sample of Adults in Nepal. *Journal of Community Health*, 41(1): 70-77. doi: 10.1007/s10900-015-0065-6
79. Shrestha, R., & Copenhaver, M. (2015). Long-Term Effects of Childhood Risk Factors on Cardiovascular Health during Adulthood. *Clinical Medicine Reviews in Vascular Health*. 7:1-5. 10.4137/CMRVH.S29964.
80. Shrestha, R., Karki, P., Suwal, A. & Copenhaver, M. (2015). Sex Trafficking Related Knowledge, Awareness, and Attitudes Among Adolescent Female Students in Nepal: A Cross-Sectional Study. *PLoS ONE*, 10(7): e0133508. doi: 10.1371/journal.pone.0133508
81. Armstrong, M.L., LaPlante, A.M., Altice, F.L, Copenhaver, M., Molina, P.E. (2015). Advancing Behavioral HIV Prevention: Adapting an Evidence-Based Intervention for People Living with HIV and Alcohol Use Disorders. *AIDS Res Treatment*, Epub 2015 Dec 1. PMID: 26697216.
82. Earnshaw VA, Smith LR, Cunningham CO, Copenhaver M. (2015). Intersectionality between internalized HIV stigma and internalized substance use stigma: Implications for depressive symptoms among PLWH with a history of substance use. *Journal of Health Psychology*, 20(8):1083-9. PubMed PMID: 24170015; NIHMSID: 753866.

83. Song, D., Altice, F., Copenhaver, M., & Long, E. (2015). Cost-Effectiveness Analysis of Brief and Expanded Evidence-Based Risk Reduction Interventions for HIV-Infected People Who Inject Drugs in the United States. *PLoS ONE* 10(2): e0116694. doi:10.1371/journal.pone.0116694
84. Ferro EG, Weikum D, Vagenas P, Copenhaver M., Gonzales P, Peinado J, et al. (2014). Alcohol Use Disorders Negatively Influence Antiretroviral Medication Adherence Among Men Who Have Sex with Men in Peru. *AIDS Care*, 1-12.
85. Belenko, S., Visher, C., Copenhaver, M., Hiller, M., Melnick, G., O'Connell, D., Pearson, F., Fletcher, B. and the HIV-STIC Workgroup of CJDATS. (2013). A cluster randomized trial of utilizing a local change team approach to improve the delivery of HIV services in correctional settings: study protocol. *Health and Justice*, 1, 1-8. Doi 10.1186/10.1186/2194-7899-1-8.
86. Baldwin, P., Shrestha, R., Potrepka, J., & Copenhaver, M. (2013). The Age of Initiation of Drug Use and Sexual Behavior May Influence Subsequent HIV Risk Behavior: A Systematic Review. *ISRN AIDS*, vol. 2013, Article ID 976035, 17 pages, 2013.
87. Copenhaver, M., Lee, I.C., & Baldwin, P. (2013). A randomized trial of the community-friendly health recovery program (CHRP) among high-risk drug users in treatment. *AIDS & Behavior*, 17, 2902-2913.
88. Belenko, S., Hiller, M., Visher, C., Copenhaver, M., O'Connell, D., Burdon, W., Pankow, J., Clarke, J., & Oser, C. (2013). Policies and practices in the delivery of HIV services in correctional agencies and facilities: Results from a multisite survey. *Journal of Correctional Health Care*, 19, 293-310.
89. Earnshaw, V.A., Smith, L.R., Chaudoir, S.R., Amico, K.R., & Copenhaver, M. (2013). HIV Stigma Mechanisms and Well-Being among PLWH: A Test of the HIV Stigma Framework. *AIDS & Behavior*, 17, 1785-1795.
90. Earnshaw, V. A., Smith, L. R., & Copenhaver, M. (2013). Drug use stigma in the context of methadone maintenance therapy: An investigation into understudied sources of stigma. *International Journal of Mental Health & Addiction*, 11, 110-122. doi: 10.1007/s11469-012-9402-5.
91. Ezeabogu, I., Copenhaver, M., & Potrepka, J. (2012). The Influence of Neurocognitive Impairment on Treatment Outcomes among Drug-involved People Living with HIV/AIDS. *AIDS Care* 24(3):386-93.
92. Copenhaver, M., Tunku, N., Ezeabogu, I., Potrepka, J., Zahari, M., Kamarulzaman, A., & Altice, F. (in press 2011). Adapting an Evidence-based Intervention Targeting HIV-infected Prisoners in Malaysia. *AIDS Research & Treatment*.
93. Copenhaver, M., Lee, I.C., Margolin, A., Bruce, R., & Altice, F. (2011). Testing an Optimized Community-Based Human Immunodeficiency Virus (HIV) Risk Reduction and Antiretroviral Adherence Intervention for HIV-Infected Injection Drug Users. *Substance Abuse*, 32(1), 16-26.
94. Copenhaver, M., Lee, I.C., Merz-Beyus, A. & Faghri, P. (2010). The Living Arrangement May Differentially Influence IDU Parents' Motivation to Reduce HIV risk as a Function of Gender. *AIDS Care*, 22(11), 1373-1378.
95. Anand, P., Springer, S., Copenhaver, M., & Altice, F. (2010). Neurocognitive Impairment and HIV Risk Factors: A Reciprocal Relationship. *AIDS & Behavior*, 14, 1213-26.

96. Copenhaver, M., Chowdhury, S., & Altice, F. (2009). Adaptation of an evidence-based intervention targeting HIV-infected prisoners transitioning to the community: The process and outcome of formative research for the Positive Living Using Safety (PLUS) intervention. *AIDS Patient Care & STDs*, 23(3), 1-11.
97. Norton, W., Amico, R., Fisher, W., Copenhaver, M., Cornman, D., Friedland, G., Kozal, M., & Fisher, J. (2008). IDU risk behavior and attitudinal correlates in a sample of HIV-infected patients in clinical care. *AIDS Care*, 20 (4), 462-469.
98. Copenhaver, M., Bruce, R., & Altice, F. (2007). Behavioral Counseling Content for Optimizing the Use of Buprenorphine for Opioid Dependence in Community Based Settings: A Review of the Empirical Evidence. *American Journal of Drug and Alcohol Abuse*, 33, 1-12.
99. Copenhaver, M., & Lee, I. (2007). Examining the decay of HIV risk reduction outcomes following a community-friendly intervention targeting injection drug users in treatment. *Journal of Psychoactive Drugs*, 39(3), 223-229.
100. Copenhaver, M., Lee, I., & Margolin, A. (2007). Successfully integrating HIV risk reduction into a community-based treatment program. *American Journal of Drug and Alcohol Abuse*, 33(1), 109-120.
101. Copenhaver, M. & Lee, I. (2006). Optimizing a Community-friendly HIV Risk Reduction Intervention for Injection Drug Users in Treatment: A Structural Equation Modeling (SEM) Approach. *Journal of Urban Health*, 83(6), 1132-1142.
102. Copenhaver, M., Johnson, B.T., Lee, I., Carey, M., & Harman, J. (2006). Behavioral HIV risk reduction among injection drug users: Meta-analytic evidence of efficacy. *Journal of Substance Abuse Treatment*, (31), 163-171.
103. Copenhaver, M., & Fisher, J. (2006). Experts outline ways to improve the decade-long U.S. trend of 40,000 new HIV infections per year. *AIDS & Behavior*, 10(1), 105-114.
104. Copenhaver, M., Margolin, A., Avants, K., & Warburton, L. (2003). Intervening effectively with drug abusers infected with HIV: Taking into account the potential for cognitive impairment. *Journal of Psychoactive Drugs*, 35(2), 209-218.
105. Margolin, A., Kantak, K., Copenhaver, M.M., Avants, K. (2003). A preliminary controlled investigation of magnesium L-aspartate hydrochloride for illicit cocaine and opiate use in methadone-maintained patients. *Journal of Addictive Diseases*, 22(2), 49-62.
106. Copenhaver, M.M. (2000). Testing a social-cognitive model of intimate abusiveness among substance dependent males. *American Journal of Drug and Alcohol Abuse*, 26(4), 603-628.
107. Copenhaver, M.M., Lash, S. J., & Eisler, R.M., (2000). Masculine Gender-Role Stress, Anger, and Male Intimate Abusiveness: Implications for Men's Relationships. *Sex Roles: A Journal of Research*, 42 (5/6), 405-414.
108. Copenhaver, M.M., & Eisler, R.M. (2000). The Development and Validation of the Feelings Toward Father Scale (FTFS): A Tool for Assessing the Father's Role in Children's Psychopathologies. *Behavior Modification*, 24(5), 740-750.

109. Lash, S.J., & Copenhaver, M.M. (1998). Masculine Gender-Role Stress and Substance Abuse Among Substance Dependent Males. *Journal of Gender, Culture, and Health*, 3(3), 183-191.
110. Copenhaver, M.M. (1996). The Role of Fathers in Their Children's Psychological Development: Implications for the Prevention of Psychopathologies. *Journal of Gender, Culture, and Health*, 1(3), 221-246.

Published book reviews, book chapters, and intervention manuals

1. Shrestha, R., Karki, P., & Copenhaver, M. (2018). Addressing the Challenges of Neuro-cognitive Impairment (NCI) on Treatment Engagement. In 'The Wiley Handbook of Patient Engagement in Healthcare Treatment: Theory, Research and Clinical Practice'. Wiley. (In press).
2. Copenhaver, M. (2016). Evidence-based intervention package (Community-friendly Health Recovery Program) disseminated by the Substance Abuse and Mental Health Services Administration (SAMHSA) National Registry of Evidence-based Programs and Practices (NREPP).
3. Copenhaver, M., Baldwin, P., Springer, S., Ezeabogu, I., & Altice, F. (2014). HIV prevention and care among drug-involved HIV-infected prisoners transitioning to the community. In H. Dlugacz (Ed), *Reentry Planning for Offenders with Mental Disorders: Policy and Practice*, Vol. II. Kingston, NJ: Civic Research Institute.
4. Copenhaver, M. (2005). Book review for Treisman and Angelino: "The psychiatry of AIDS, A guide to diagnosis and treatment". Baltimore, MD: Johns Hopkins University Press.
5. Copenhaver, M., & Eisler, R.M. (1996). Masculine gender role stress: A perspective on men's health. In P.M. Kato (Ed.), *Health psychology of special populations: Issues in age, gender, and ethnicity*. New York: Plenum.

Invited Presentations

1. Izadidehkordi, S., & Copenhaver, M. (March, 2025). A Randomized Clinical Trial Targeting Pre-Exposure Prophylaxis Adherence in Opioid Replacement Therapy Patients participating in the Bio-behavioral Community-friendly Health Recovery Program (CHRP-BB). Abstract for American Public Health Association (APHA) 2025 Annual Meeting and Expo.
2. Izadidehkordi, S., & Copenhaver, M. (March, 2025). An Integrated Biochemical Behavioral Intervention to Enhance PrEP Adherence. Poster Presentation, Biomedical HIV Prevention at USCHA 2025.
3. Gautam, K., Paudel, K.*, Wickersham, JA., Bellia, G., Altice, FL., JadKarim, L., Liew, Z., Khati, A.*, Copenhaver, M., & Shrestha, R. (2025). Feasibility and acceptability of daily oral emtricitabine and tenofovir alafenamide fumarate (FTC/TAF) for HIV pre-exposure prophylaxis among opioid-dependent people who inject drugs. Society of Behavioral Medicine's 46th Annual Meeting & Scientific Sessions. San Francisco, CA, United States.
4. Gautam, K., Paudel, K.*, Wickersham, JA., Bellia, G., Altice, FL., JadKarim, L., Liew, Z., Khati, A.*, Copenhaver, M., & Shrestha, R. (2024). Feasibility and acceptability of

daily oral emtricitabine and tenofovir alafenamide fumarate (FTC/TAF) for HIV pre-exposure prophylaxis among opioid-dependent people who inject drugs. Round table presentation at the American Public Health Association Annual Meeting 2024, Minneapolis, USA.

5. Khati, A., Altice, F.L., Copenhaver, M., Xu, R., Wickersham, J.A., Gautam, K., Paudel, K., & Shrestha, R. (2025). Uptake and persistence on oral pre-exposure prophylaxis (PrEP) among opioid-dependent people who inject drugs initiating PrEP for HIV prevention. Poster presentation at the 46th Annual Meeting of the Society of Behavioral Medicine, Context Matters: Bridging Perspectives in Behavioral Medicine. San Francisco, CA, United States.

6. Sujan, M.**, Wickersham, J.**, Khati, A.**, Gautam, K.**, Paudel, K., Azwa, I., Altice, F., Tan, Y., Sahira, N., Copenhaver, M., Shrestha, R. (2024). Exploring perceived utility of a clinic integrated HIV prevention app among men who have sex with men in Malaysia: A think-aloud study. Poster Presentation at the 2025 STI & HIV World Congress, Montreal, Canada.

7. Khati, A.**, Wickersham, J., Copenhaver, M., Xu, R., Gautam, K.**, Paudel, K.**, JadKarim, L.**, Sujan, S.**, & Shrestha, R. (2024). Persistence in Pre-Exposure Prophylaxis (PrEP) Receipt Post-Prescription Among People Who Inject Drugs. Poster Presentation at the 25th International AIDS Conference. July 2024. Munich, Germany.

8. Gautam, K.**, Paudel, K.**, Wickersham, J.A., Bellia, G.**, Altice, F.L., JadKarim, L.**, Liew, Z., Khati, A.**, Copenhaver, M., & Shrestha, R. (2024). Feasibility and acceptability of daily oral emtricitabine and tenofovir alafenamide fumarate (FTC/TAF) for HIV pre-exposure prophylaxis among opioid-dependent people who inject drugs. Poster Presentation at the 25th International AIDS Conference. July 2024. Munich, Germany.

9. Mistler, C., Edelman, E.J., Meyer, J., & Copenhaver, M. (2024). The Association Between Cognitive Impairment and Quality of Life Among Individuals on Medication for Opioid Use Disorder. Live Research Spotlight at the 45th Annual Meeting & Scientific Sessions of the Society of Behavioral Medicine, Philadelphia, PA.

10. Mistler, C., Edelman, E.J., Meyer, J., Copenhaver, M. (2024) The Association between Cognitive Impairment and Quality of Life among Individuals on Medication for Opioid Use Disorder. Research Spotlight at the Society of Behavioral Medicine Annual Meeting.

11. Mistler, C., Copenhaver, M., Shrestha, R., & Gunstad, J. (2023). Impact of Impaired Cognitive Functioning Among Persons on Medication for Opioid Use Disorder. Oral presentation at the 85th Annual Conference of the College on Problems of Drug Dependence (CPDD). Denver, Colorado.

12. Mistler, C., Copenhaver, M., Shrestha, R., & Gunstad, J. (2023). Impact of Impaired Cognitive Functioning Among Persons on Medication for Opioid Use Disorder. Oral presentation at the 85th Annual Conference of the College on Problems of Drug Dependence (CPDD). Denver, Colorado.

13. Sullivan MC, Cruess DG, Sibilio B, Shrestha R, Copenhaver M (2023). Perceived risk of HIV infection and self-reported adherence to pre-exposure prophylaxis (PrEP) among people who inject drugs engaged in medication treatment for opioid use disorder. Poster presentation at the Annual Convention of the Association for Behavioral and Cognitive Therapies.

14. Sullivan, M. & Copenhaver, M. (2023). Stigma, coping, and HIV pre-exposure prophylaxis adherence and persistence in people with opioid use disorder in treatment. Invited talk presented as part of the Early Stage Investigator Spotlight Seminar: Inter-CFAR Substance Use Research Community (I-SURC).
15. Mistler, C. & Copenhaver, M. (2022). Integrating Cognitive Dysfunction Accommodation Strategies into HIV Prevention Behavioral Interventions: A 2-Arm Pilot Feasibility Study. International AIDS Conference. Montreal.
16. Mistler, C., Idiong, C., Copenhaver, M. (2022). Cognitive Dysfunction Accommodation Strategies for Behavioral Interventions: Outcomes of Focus Group Research. Poster presentation at the Society of Behavioral Medicine Annual Meeting, Baltimore, MD.
17. Mistler, C., Sullivan, M., Copenhaver, M., Meyer, J., Roth, A., Shenoi, S., Edelman, E.J., Wickersham, J., Shrestha, R. (2021). Racial and Ethnic Differences in the Impacts of COVID-19 Pandemic Among People with Opioid Use Disorder. Research Spotlight at the Society of Behavioral Medicine Annual Meeting. Virtual Conference.
18. Mistler, C., Chandra, D., Copenhaver, M., Wickersham, J., Shrestha, R. (2021). Engagement in harm reduction strategies after suspected fentanyl contamination among opioid-dependent individuals. Meritorious Abstract, Research Talk at the Society of Behavioral Medicine Annual Meeting. Virtual Conference.
19. Sullivan, M., Mistler, C., Copenhaver, M., Wickersham, J., Ni, Z., Kim, R., and Shrestha, R. (2021). Racial differences in willingness to vaccinate against COVID-19 in people with Opioid Use Disorder. Society for Behavioral Medicine 2021 Annual Meeting. April 12-16: Virtual Conference.
20. Mistler, C., Sullivan, M., Copenhaver, M., Meyer, J., Roth, A., Shenoi, S., Edelman, E.J., Wickersham, J., Shrestha, R. (2021). Racial and Ethnic Differences in the Impacts of COVID-19 Pandemic Among People with Opioid Use Disorder. E-poster presentation at the International AIDS Society COVID-19 Conference: Prevention. Virtual Conference.
21. Mistler, C. (2020, 2021). Opioid Prevention for Adolescent Youth. Oral presentation at Tri-County Regional Technical Vocational High School, Franklin, MA.
22. Mistler, C., Copenhaver, M., Shrestha, R. (2020). The Pre-exposure Prophylaxis (PrEP) Care Cascade in People Who Inject Drugs: A Systematic Review. Roundtable Session Presentation at the American Public Health Association Annual Meeting and Expo. Virtual Conference.
23. Mistler, C., Copenhaver, M., Shrestha, R. (2020). The Pre-exposure Prophylaxis (PrEP) Care Cascade in People Who Inject Drugs: A Systematic Review. Roundtable Session Presentation at the American Public Health Association Annual Meeting and Expo (Virtual).
24. Shrestha, R., DiDomizio, L., Kim, R., Altice, F., Wickersham, J., & Copenhaver, M. (2020). Awareness about and interest in long-acting injectable pre-exposure prophylaxis (LAIP) use in people who use drugs. Poster presentation at the 12th International Women's and Children's Health and Gender (InWomen's) Group conference. Hollywood, Florida.
25. Shrestha, R., Altice, F., & Copenhaver, M. (2019). HIV Testing Practices and Reasons for Never-Testing among Men Who Have Sex with Men (MSM) in Malaysia.

Poster presentation at the 10th IAS Conference on HIV Science (IAS 2019). Mexico City, Mexico.

26. Shrestha, R., Altice, F., & Copenhaver, M. (2019). Preferences for long-acting injectable (LAI) versus daily oral pre-exposure prophylaxis (PrEP) among high-risk drug users. Poster presentation at the 147th American Public Health Association (APHA) Conference. Philadelphia, Pennsylvania.

27. Shrestha, R., Ahmad, A., & Altice, F. (2019). Impact of Methadone Dose on Post-Release Linkage to Treatment among Incarcerated HIV-Infected Individuals Transitioning to the Community in Malaysia. Poster presentation at the 147th American Public Health Association (APHA) Conference. Philadelphia, Pennsylvania.

28. Ranjit, Y., Shrestha, R., Copenhaver, M., & Altice, F. (2019). Online Information Seeking and Pre-Exposure Prophylaxis awareness among Drug Users Without HIV. Poster presentation at the National Communication Association (NCA) 105th Annual Convention. Baltimore, Maryland.

29. Shrestha, R., Altice, F., & Copenhaver, M. (2019). Antiretroviral Therapy (ART) Adherence among HIV-Infected Opioid-Dependent Patients: The Role of HIV-Related Stigma and Motivation to Adhere to ART. Poster presentation at the 2019 National HIV Prevention Conference (NHPC). Georgia, USA.

30. Shrestha, R., Altice, F., & Copenhaver, M. (2019). Use of Smartphone to Find Sexual Health Information Online Among Malaysian MSM: Implications for mHealth Intervention. Accepted for poster presentation at the 40th Annual Meeting & Scientific Sessions of the Society of Behavioral Medicine. Washington, DC, USA.

31. Shrestha, R., Altice, F., & Copenhaver, M. (2019). Feasibility and Acceptability of an mHealth-Based Strategy to Improve Adherence to Pre-Exposure Prophylaxis among Drug Users. Accepted for poster presentation at the 40th Annual Meeting & Scientific Sessions of the Society of Behavioral Medicine. Washington, DC, USA.

32. Shrestha, R., Ni, Z., Copenhaver, M., Altice, F., & Lim, S. (2019). HIV testing practices and reasons for never-testing among men who have sex with men (MSM) in Malaysia. Poster presentation at the Annual Conference of the College on Problems of Drug Dependence (CPDD). San Antonio, TX.

33. Shrestha, R., Altice, F., Ssenyonjo, J., Sibilio, B., & Copenhaver, M. (2019). Testing an integrated bio-behavioral approach to improve adherence to pre-exposure prophylaxis and HIV risk reduction among methadone-maintained patients: The CHRP-BB study. Poster presentation at the Annual Conference of the College on Problems of Drug Dependence (CPDD). San Antonio, TX.

34. Shrestha, R., Altice, F., & Copenhaver, M. (2019). Opioid-Dependent Women in Violent Relationship Are More Likely to Show Sub-Optimal Adherence to Pre-Exposure Prophylaxis (PrEP): Implications for Primary HIV Prevention. Poster presentation at the 11th International Women's and Children's Health and Gender (InWomen's) Group Conference. San Antonio, TX.

35. Shrestha, R., Altice, F., & Copenhaver, M. (2019). Preliminary Evidence for Feasibility and Acceptability of an mHealth-Based Strategy to Improve Adherence to Pre-Exposure Prophylaxis (PrEP) among Drug Users. Accepted for oral presentation at the 2019 National HIV Prevention Conference (NHPC). Georgia, USA.

36. Shrestha, R., Altice, F., & Copenhaver, M. (2019). HIV-Related Stigma, Motivation to Adhere to Medication, and ART Adherence among HIV-Positive Methadone-

- Maintained Patient. Accepted for oral presentation at the 40th Annual Meeting & Scientific Sessions of the Society of Behavioral Medicine. Washington, DC, USA.
37. Shrestha, R. & Copenhaver, M. (2018). Exploring the Use of Pre-Exposure Prophylaxis (PrEP) for HIV Prevention among High Risk Drug Users in Treatment. Roundtable presentation at the 146th American Public Health Association (APHA) Conference. San Diego, California.
38. Shrestha, R. & Copenhaver, M. (2018). Perceived HIV Risk Mediates the Relationship Between HIV Risk Behavior and Willingness to Use Pre-Exposure Prophylaxis (PrEP) among Drug Users. Poster presentation at the Annual Conference of the College on Problems of Drug Dependence (CPDD). San Diego, California.
39. Shrestha, R., Altice, F., Karki, P., & Copenhaver, M. (2018). Integrated biobehavioral approach to improve adherence to pre-exposure prophylaxis and reduce HIV risk in people who use drugs. Oral presentation at the 39th Annual Meeting & Scientific Sessions of the Society of Behavioral Medicine. New Orleans, Louisiana.
40. Shrestha, R., & Copenhaver, M. (2018). Experiences Using Pre-Exposure Prophylaxis for HIV Prevention among High Risk Drug Users. Oral presentation at the 39th Annual Meeting & Scientific Sessions of the Society of Behavioral Medicine. New Orleans, Louisiana.
41. Ssenyonjo, J., Shrestha, R., & Copenhaver, M. (2018). Stigma May Influence Willingness and Uptake of Pre-Exposure Prophylaxis (PrEP) Among High-risk Populations. Poster presentation at the University of Connecticut Graduate Student Research Forum. Storrs, Connecticut.
42. Shrestha, R., Altice, F., Huedo-Medina, T., Karki, P., & Copenhaver, M. (2017). Willingness to Use Pre-Exposure Prophylaxis (PrEP): An Empirical Test of the Information-Motivation-Behavioral Skills (IMB) Model among High-Risk Drug Users in Treatment. Oral presentation at the 145th American Public Health Association (APHA) Conference. Atlanta, Georgia.
43. Shrestha, R., Altice, F., Karki, P., & Copenhaver, M. (2017). Developing an Integrated, Brief Bio-Behavioral HIV Prevention Intervention for High Risk Drug Users in Treatment: Taking into Account the Impact of Neurocognitive Impairment. Oral presentation at the 145th American Public Health Association (APHA) Conference. Atlanta, Georgia.
44. Shrestha, R., Karki, P., Altice, F., & Copenhaver, M. (2017). Using conjoint analysis to measure the acceptability of pre-exposure prophylaxis (PrEP) use for HIV prevention among high-risk drug users in treatment. Poster presentation at the 9th IAS Conference on HIV Science. Paris, France.
45. Shrestha, R., Altice, F., Huedo-Medina, T., Karki, P., & Copenhaver, M. (2017). Willingness to Use Pre-Exposure Prophylaxis (PrEP): An Empirical Test of the Information-Motivation-Behavioral Skills (IMB) Model among High Risk Drug Users in Treatment. Poster presentation at the 9th IAS Conference on HIV Science. Paris, France.
46. Shrestha, R., Altice, F., Karki, P., Huedo-Medina, T., & Copenhaver, M. (2017). Feasibility, acceptability, and preliminary efficacy of the Bio-Behavioral Community-friendly Health Recovery Program (CHRP-BB): A combination approach for primary HIV prevention among high risk drug users. Poster presentation at the 9th IAS Conference on HIV Science. Paris, France.

47. Shrestha, R., Karki, P., Altice, F., & Copenhaver, M. (2017). Correlates of willingness to use Pre-Exposure Prophylaxis (PrEP) among high-risk drug users in treatment. Oral presentation at the 38th Annual Meeting & Scientific Sessions of the Society of Behavioral Medicine. San Diego, California.
48. Shrestha, R., Karki, P., Altice, F., & Copenhaver, M. (2017). Feasibility, Acceptability, and Preliminary Efficacy of an Integrated Bio-Behavioral Approach for Adherence to Pre-Exposure Prophylaxis (PrEP) and HIV Risk Reduction among High Risk Drug Users. Oral presentation at the University of Connecticut Graduate Student Research Forum. Storrs, Connecticut.
49. Shrestha, R., Altice, F., & Copenhaver, M. (2017). Examining the Acceptability of mHealth Technology in HIV Prevention among High-risk Drug Users in Treatment. Poster presentation at the 38th Annual Meeting & Scientific Sessions of the Society of Behavioral Medicine. San Diego, California.
50. Shrestha, R., Karki, P., Altice, F., & Copenhaver, M. (2017). Developing a Bio-Behavioral HIV Intervention for High-Risk Drug Users: Taking into Account Impact of Neurocognitive Impairment. Poster presentation at the 38th Annual Meeting & Scientific Sessions of the Society of Behavioral Medicine. San Diego, California.
51. Karki, P., Shrestha, R., Altice, F., Huedo-Medina, T., & Copenhaver, M. (2017). Correlates of willingness to use Pre-Exposure Prophylaxis (PrEP) among high-risk drug users in treatment. Poster presentation at the University of Connecticut Graduate Student Research Forum. Storrs, Connecticut.
52. Shrestha, R., Karki, P., Copenhaver, M., & Altice, F. (2016). The Moderating Role of Treatment Engagement on the Relationship between Neurocognitive Impairment and Antiretroviral Treatment (ART) Adherence. Poster presentation at the HIV Drug Therapy Glasgow. Glasgow, UK.
53. Shrestha, R., Karki, P., Huedo-Medina, T., & Copenhaver, M. (2016). The Moderating Role of Treatment Engagement on the Relationship between Neurocognitive Impairment and Antiretroviral Treatment (ART) Adherence. Poster presentation at the 18th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV. New York, NY.
54. Shrestha, R., Huedo-Medina, T., Karki, P., & Copenhaver, M. (2016). Modeling a Theory-Based Approach to Examine the Influence of Neurocognitive Impairment on HIV Risk Reduction Behaviors among Drug Users. Poster presentation at the annual conference of the College on Problems of Drug Dependence (CPDD). Palm Springs, California.
55. Shrestha, R., Karki, P., & Copenhaver, M. (2016). An Exploratory Factor Analysis of a Brief Self-Report Scale to Detect Neurocognitive Impairment Among Participants Enrolled in Methadone Maintenance Therapy. Poster presentation at the annual conference of the College on Problems of Drug Dependence (CPDD). Palm Springs, California.
56. Shrestha, R., & Copenhaver, M. (2016). Association between Intimate Partner Violence and STI/HIV-Related Risk Behaviors: Findings from the Nepal Demographic Health Survey. Poster presentation at the Ending Gender Inequalities: Addressing the Nexus of HIV, Drug Use, and Violence with Evidence-based Action conference. Chapel Hill, NC.

57. Shrestha, R., Karki, P., Altice, F., & Copenhaver, M. (2016). Feasibility, Acceptability, and Preliminary Efficacy of an Integrated Bio-Behavioral Approach for Adherence to Pre-Exposure Prophylaxis (PrEP) and HIV Risk Reduction among High Risk Drug Users. Oral presentation at the University of Connecticut Graduate Student Research Forum. Storrs, Connecticut.
58. Shrestha, R., Karki, P., Copenhaver, M., & Altice, F. (2016). Moderating Role of Treatment Engagement on the Relationship between Neurocognitive Impairment and Antiretroviral Treatment (ART) Adherence. Oral presentation at the 2016 Connecticut Public Health Association Annual Conference. New Haven, Connecticut.
59. Copenhaver, M. Shrestha, R., Huedo-Medina, T., Karki, P., & Altice, F. (2016). An Exploratory Factor Analysis of a Brief Self-Report Scale to Detect Neurocognitive Impairment among Participants Enrolled in Methadone Maintenance Therapy. Presentation at the annual conference of the College on Problems of Drug Dependence (CPDD). Palm Springs, California.
60. Shrestha, R., Huedo-Medina, T., Karki, P., & Copenhaver, M. (2016). Modeling a Theory-Based Approach to Examine the Influence of Neurocognitive Impairment on HIV Risk Reduction Behaviors among Drug Users. Oral presentation at the 144th American Public Health Association (APHA) Conference. Denver, Colorado.
61. Shrestha, R., Weikum, D., Copenhaver, M., & Altice, F. (2016). Influence of Neurocognitive Impairment, Depression, and Alcohol Use Disorders on Quality of Life among Incarcerated, HIV-Positive Opioid Dependent Malaysian Men: A Moderated Mediation Analysis. Oral presentation at the 144th American Public Health Association (APHA) Conference. Denver, Colorado.
62. Karki, P., Shrestha, R., & Copenhaver, M. (2016). The Use of Female Sex Workers among Men in Nepal: Prevalence, STIs/HIV-Related Risk Behaviors, and Gender Ideology. Oral presentation at the 144th American Public Health Association (APHA) Conference. Denver, Colorado.
63. Shrestha, R., Copenhaver, M., & Altice, F. (2016). A moderated mediating model of stigma, depression, and social support on quality of life among incarcerated, HIV-positive men with opioid dependence in Malaysia. Oral presentation at the 144th American Public Health Association (APHA) Conference. Denver, Colorado.
64. Ahmed, T., Shrestha, R., Huedo-Medina, T., & Copenhaver, M. (2016). Self-efficacy mediates the effect of neurocognitive impairment on HIV risk reduction intervention outcomes among high-risk drug users in treatment. Oral presentation at the 144th American Public Health Association (APHA) Conference. Denver, Colorado.
65. Shrestha, R., Huedo-Medina, T., Karki, P., & Copenhaver, M. (2016). Modeling a Theory-Based Approach to Examine the Influence of Neurocognitive Impairment on HIV Risk Reduction Behaviors among Drug Users. Presentation at the annual conference of the College on Problems of Drug Dependence (CPDD). Palm Springs, California.
66. Armstrong, M.L., LaPlante, A.M., Ferguson, T.F., Ruiz, M., Besch, C.L., Clark, R., Bryant, K.J., Altice, F.L., Copenhaver, M., & Molina, P.E. (2016, June). The Effectiveness of an Alcohol Harm Reduction Intervention among PLWHA: Preliminary Findings. Poster abstract accepted to the Annual Conference for Research Society on Alcoholism, New Orleans, Louisiana.
67. Shrestha, R., Karki, P., & Copenhaver, M. (2016). An Exploratory Factor Analysis of a Brief Self-Report Scale to Detect Neurocognitive Impairment Among Participants

- Enrolled in Methadone Maintenance Therapy. Presentation at the annual conference of the College on Problems of Drug Dependence (CPDD). Palm Springs, California.
68. Shrestha, R., & Copenhaver, M. (2016). Association between Intimate Partner Violence and STI/HIV-Related Risk Behaviors: Findings from the Nepal Demographic Health Survey. Poster presentation at the Ending Gender Inequalities: Addressing the Nexus of HIV, Drug Use, and Violence with Evidence-based Action conference. Chapel Hill, NC.
69. Shrestha, R., & Copenhaver, M. (2015). Association between Intimate Partner Violence and STI/HIV-Related Risk Behaviors: Findings from the Nepal Demographic Health Survey. Oral presentation at the 143rd American Public Health Association (APHA) Conference. Chicago, IL.
70. Shrestha, R., Karki, P., & Copenhaver, M. (2015). Early Sexual Debut: A Risk Factor for STIs/HIV Acquisition among a Nationally Representative Sample of Adults in Nepal. Oral presentation at the 3rd International Conference on HIV/AIDS, STDs & STIs. Atlanta, GA.
71. Shrestha, R., Huedo-Medina, T., & Copenhaver, M. (2015). Sex-Related Differences in Self-Reported Neurocognitive Impairment among High-Risk Cocaine Users in Methadone Maintenance Treatment Program. Poster presentation at the 143rd American Public Health Association (APHA) Conference. Chicago, IL.
72. Shrestha, R., & Copenhaver, M. (2014). Association between intimate partner violence against women and HIV risk behaviors: Findings from the Nepal Demographic Health Survey. Oral presentation at the 2014 CHOP Global Health Conference. Philadelphia, PA.
73. Shrestha, R., & Copenhaver, M. (2014). Developing an evidence-based intervention targeting high-risk migrant workers. Presentation at the annual conference of the College on Problems of Drug Dependence (CPDD). San Juan, Puerto Rico.
74. Copenhaver, M. (2014). Developing Optimal Evidence-based HIV Prevention Interventions for Real World Settings. Oral presentation to the Advisory Board of the Department of Allied Health Sciences.
75. M.L. Armstrong, A.M. LaPlante, M. Booth, N. Zhang, S. Moody-Thomas, C.L. Besch, R. Clark, K.J. Bryant, F. L. Altice, M. Copenhaver, P.E. Molina (2014). Adapting an evidence-based intervention to decrease alcohol use disorders (AUDs) among people living with HIV/AIDS (PLWHA). Research Society on Alcoholism conference, Bellevue, Washington.
76. Ferro EG, Weikum D, Vagenas P, Copenhaver MM, Gonzales P, Peinado J, Lama JR, Sanchez J, Altice FL. Alcohol Use Disorders Negatively Influences Antiretroviral Medication Adherence Among Men Who Have Sex with Men and Transgender Women in Peru. 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention, June 30-July 3; 2013; Kuala Lumpur, Malaysia; Abstract A-581-0195-01733.
77. Copenhaver, M., & Shrestha, R. (June, 2013). "Using a non-inferiority trial approach to test the Holistic Health for HIV (3H+) intervention among HIV+ drug users in treatment". Presentation at the annual conference of the College on Problems of Drug Dependence (CPDD). San Diego, CA.
78. Shrestha, R., & Copenhaver, M. (June, 2013). HIV risk behaviors among returnee male migrant workers in Nepal. Presentation at the annual conference of the College on Problems of Drug Dependence (CPDD). San Diego, CA.

79. Ferro EG, Weikum D, Vagenas P, Copenhaver MM, Gonzales P, Peinado J, Lama JR, Sanchez J, Altice FL. Alcohol Use Disorders Negatively Influences Antiretroviral Medication Adherence Among Men Who Have Sex with Men and Transgender Women in Peru. 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention, June 30-July 3; 2013; Kuala Lumpur, Malaysia; Abstract A-581-0195-01733.
80. Copenhaver, M. (January, 2013). Adapting Evidence-based Interventions for Optimal Implementation in Clinical Settings. Invited presentation at the Center for Research on AIDS, Yale University, New Haven, CT.
81. Earnshaw, V. A., Smith, L. R., Chaudoir, S. R., Amico, K. R., & Copenhaver, M. M. (August, 2013). Individual level HIV stigma mechanisms: Do we need to differentiate? Oral presentation at the annual convention of the American Psychological Association. Honolulu, HI.
82. Copenhaver, M. (September, 2012). Adapting Evidence-based Interventions for Optimal Implementation with Drug-involved Persons. Invited presentation at the Center for Health, Intervention, & Prevention's lecture series. Storrs, CT.
83. Copenhaver, M. (September, 2012). Testing an adapted evidence-based HIV prevention intervention in a clinical setting. Invited presentation at the 2012 National Hispanic Science Network on Drug Abuse (NHSN) annual conference. San Diego, CA.
84. Earnshaw, V., Smith, V., Chaudoir, S., Lee, I., & Copenhaver, M. (2012). Concealable Stigma: Interpersonal Processes and Implications for Health Disparities Policy. Presentation at the biennial Society for the Psychological Study of Social Issues (SPSSI) convention. Charlotte, NC.
85. Pich, M., Belenko, S., Copenhaver, M., O'Connell, D., Pearson, F., Oser, C. et al. (2012). Inmate perceptions of HIV services. American Society of Criminology Annual Conference, Chicago, IL.
86. Sadeghi, M., & Copenhaver, M. (2012). The influence of neurocognitive impairment on HIV risk reduction outcomes among opioid-dependent patients. Presentation at the annual conference of the College on Problems of Drug Dependence (CPDD). Palm Springs, CA.
87. Ezeabogu, I., & Copenhaver, M. (2012). Factors that contribute to successful prison-based HIV risk-reduction interventions. Presentation at the annual conference of the College on Problems of Drug Dependence (CPDD). Palm Springs, CA.
88. Copenhaver, M. (2012). Testing an adapted evidence-based HIV prevention intervention in a drug treatment setting. Presentation at the annual conference of the College on Problems of Drug Dependence (CPDD). Palm Springs, CA.
89. Ezeabogu, I., & Copenhaver, M. (2010). The influence of neuro-cognitive impairment on intervention outcomes among injection drug users living with HIV/AIDS. Presentation at the annual conference of the College on Problems of Drug Dependence (CPDD). Scottsdale, AZ.
90. Potrepka, J., & Copenhaver, M. (2010). The impact of age of drug use debut on subsequent HIV risk behavior among injection drug users. Presentation at the annual conference of the College on Problems of Drug Dependence (CPDD). Scottsdale, AZ.
91. Copenhaver, M. (October, 2009). Guest speaker (for Dr. Pouran Faghri, AHS), 'Changing and evaluating motivation to reduce HIV risk among drug users in treatment'. Storrs, CT.

92. Copenhaver, M. (November, 2009). Guest speaker (for Dr. Fridell, AHS), 'Adapting behavioral interventions to address health risk behaviors among priority populations.' Storrs, CT.
93. Copenhaver, M., Evans, L., Sylla, L., Boticello, P., MacGowan, R., & Altice, F. (August, 2009). Positive Living Using Safety (PLUS): Evaluation of an HIV risk reduction intervention for HIV-infected prisoners. Presentation at the National Conference on HIV Prevention (NCHP) annual conference. Atlanta, GA.
94. Copenhaver, M., Merz, A. (g), & Lee, I.C. (June, 2008). Children as Motivation to Reduce HIV Risk: Gender Differences Between IDU Parents in Treatment. Presentation at the College on Problems of Drug Dependence (CPDD) annual conference. San Juan, Puerto Rico.
95. Amaechi, O. (g), Lee, I.C., & Copenhaver, M. (June, 2008). A Brief Behavioral Intervention to Enhance Medication Adherence Among HIV-infected Injection Drug Users. Presentation at the College on Problems of Drug Dependence (CPDD) annual conference. San Juan, Puerto Rico.
96. Bruce, R.D., Acosta, A. (g), Copenhaver, M., & Altice, F.L. (June, 2008). Hepatitis C Treatment Among Methadone-Maintained Patients: Directly-Observed Therapy Compared with Standard-of-Care. Presentation at the College on Problems of Drug Dependence (CPDD) annual conference. San Juan, Puerto Rico.
97. Copenhaver, M. (October, 2007). Guest speaker (for Dr. Pouran Faghri), 'Optimizing HIV risk reduction using Multiple Levels of Analysis'. Storrs, CT.
98. Copenhaver, M. (October, 2007). Guest speaker (for Dr. Valerie Duffy), 'Changing HIV Risk Behavior Among Injection Drug Users: A Harm Reduction Model'. Storrs, CT.
99. Copenhaver, M. (November, 2007). Allied Health Sciences colloquium, 'Reducing HIV Risk Behavior Among IDUs: Philosophy, Ingredients, & Implementation'. Storrs, CT.
100. Copenhaver, M. (March, 2008). Guest speaker (for Maryann Morris), 'Using Motivation to Reduce HIV Risk Behavior Among Drug Users'. Storrs, CT.
101. Copenhaver, M. (February, 2008). Guest speaker for graduate seminar course in health intervention research (for instructor Dr. Seth Kalichman), "Reducing HIV risk among HIV infected prisoners". Storrs, CT.
102. Copenhaver, M., Bruce, R., & Altice, F. (June, 2007). The feasibility of delivering a brief HIV risk reduction intervention targeting HIV-infected IDUs in a community-based setting. Presentation at the annual conference of the College on Problems of Drug Dependence (CPDD). Quebec City, Canada.
103. Altice, F., Copenhaver, M., & Bruce, R. (June, 2007). A review of behavioral counseling content for optimizing the use of buprenorphine for treating opioid-dependence in U.S. drug-treatment CBOs. Presentation at the annual conference of the College on Problems of Drug Dependence (CPDD). Quebec City, Canada.
104. Copenhaver, M. (October, 2006). Moving toward an optimized HIV risk reduction Intervention targeting drug users. Invited presentation at the Center for Health, Intervention, & Prevention's lecture series. Storrs, CT.
105. Lee, I.C. & Copenhaver, M. (June, 2006). Refining an HIV risk reduction intervention using a structural equations modeling (SEM) approach. Presentation at the annual conference of the College on Problems of Drug Dependence (CPDD). Scottsdale, AZ.

106. Copenhaver, M. & Lee, I.C. (June, 2006). Examining the potency of a community-friendly HIV risk reduction intervention. Presentation at the annual conference of the College on Problems of Drug Dependence (CPDD). Scottsdale, AZ.
107. Altice, F., Copenhaver, M., Bruce, R.A. (June, 2006). Integrating evidence-based counseling with routine buprenorphine treatment for opiate dependence. Presentation at the annual conference of the College on Problems of Drug Dependence (CPDD). Scottsdale, AZ.
108. Copenhaver, M., Lee, I.C., Harman, J., Johnson, B.T., & Carey, M. (August, 2005). Key components in behavioral HIV risk reduction interventions targeting injection drug users: A meta-analysis. Invited poster presentation given at the NIDA K-grant awardee conference. Bethesda, MD.
109. Lee, I.C. & Copenhaver, M. (2005). HIV risk reduction can be integrated into substance abuse treatment. Oral presentation at the annual conference of the College on Problems of Drug Dependence (CPDD). Orlando, FL.
110. Copenhaver, M., Lee, I.C., Harman, J., Johnson, B.T., & Carey, M. (2005). Specifying the key components of HIV risk reduction interventions targeting IDUs. Poster presentation at the annual conference of the College on Problems of Drug Dependence (CPDD). Orlando, FL.
111. Fisher, J.D. & Copenhaver, M. (2005). Experts outline ways to improve the trend of 40,000 new infections per year in the U.S. Poster presentation at the annual conference of the College on Problems of Drug Dependence (CPDD). Orlando, FL.
112. Copenhaver, M. (2004, September). Invited panel member for NIH/NIDA, "Integrating HIV Prevention in Substance Abuse Treatments". Bethesda, MD.
113. Copenhaver, M. (2004, March). Invited panel member for NIH/NIDA, "Phase IV Randomized, Controlled Study to Optimize the Concurrent Use of Buprenorphine & Highly Active Anti-Retroviral Therapy in HIV+ Opioid Dependent Persons", Tampa, FL.
114. Copenhaver, M. (2003, October). Invited panel member for NIH/NIDA, "Integrating Treatment with Buprenorphine and HAART", Rockville, MD.
115. Copenhaver, M. (2003, June). "Behavioral Interventions for Substance Abusers with Cognitive Impairment". Invited presentation given as a panel member at the National Institutes of Health/National Institute on Drug Abuse (NIH/NIDA) meeting, Bethesda, MD.
116. Copenhaver, M. (2002, November). "HIV Harm Reduction Interventions for Substance Abusers: Taking into Account Cognitive Impairment". Invited presentation given at the Social Division lecture series, University of Connecticut, Psychology Department, Storrs, CT.
117. Copenhaver, M. (2002). "Behavioral Treatment Interventions for HIV+ Methadone-Maintained Patients". Invited symposium given at the American Society of Addiction Medicine conference, Atlanta, GA.
118. Copenhaver, M. & Warburton, L. (2001). "Holistic HIV Harm Reduction Intervention In-Service for Substance Abuse Counselors". In-Service given at the APT Foundation Continuing Education for CADAC Certified Counselors, May 4, 2001.
119. Copenhaver, M., and Usubiaga, H. (2001). "HIV Harm Reduction Intervention In-Service for Substance Abuse Counselors". In-Service given at Department of Psychiatry Psychotherapy Seminar Series.
120. Copenhaver, M., and Usubiaga, H. "Harm Reduction Approach to HIV-Prevention

121. Interventions" (2002). In-Service given at Department of Psychiatry Seminar Series.
122. Copenhaver, M.M., Moore, T., & Rhatigan, D. (1999). Testing a social-cognitive model of male intimate abusiveness among substance-dependent males. Poster presented at the Association for the Advancement of Behavior Therapy.
123. Copenhaver, M.M., & Eisler, R.M. (1995). Development and validation of the attitudes toward Father Scale (ATFS). Poster presented at the Association for the Advancement of Behavior Therapy conference, Washington, DC.
124. Copenhaver, M.M., and Youngberg, R. (1993). Predictors of Suicide Intent: Hopeless as a Critical Measure. Paper presented at Western Pennsylvania Psychological Association conference, Pittsburgh, PA.
125. Copenhaver, M.M., Wright, J.E., Youngberg, R., and Beck, A.T. (1992). Predictors of Suicide Intent. Paper presented at American Psychological Association, Washington, DC.
126. Copenhaver, M.M. (1989). The Effect of Spatial Contrast Sensitivity on Pseudoisochromatic Test Performance. Thesis presented at Villanova University, Villanova, PA.
127. Copenhaver, M.M., and Dane, F.C. (1987). The Quantification of Reasonable Doubt. Paper presented at the Southeastern Psychological Association, Atlanta, GA.